A real‐world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin‐containing therapies

Author:

Gao Wen1,Xu Ying1,Liu Jianxiang1,Wang Xiaolei1,Dong Xinhong1,Teng Guigen1,Liu Binbin1,Dong Jinpei1,Ge Chaoyi1,Ye Hui2,Zhang Xuezhi2,Cheng Hong1ORCID

Affiliation:

1. GI Department Peking University First Hospital Beijing China

2. TCM and Integrative Medicine Department Peking University First Hospital Beijing China

Abstract

AbstractBackgroundThe treatment of Helicobacter pylori (H. pylori) infection is a challenge for those who cannot use amoxicillin.ObjectiveTo evaluate the eradication rate and adverse effects of vonoprazan and tetracycline dual therapy as first‐line and rescue treatment regimens used in special populations with penicillin allergy or failed in previous amoxicillin‐containing therapies.DesignPatients enrolled were those who were H. pylori‐positive with selected conditions: (1) allergic to penicillin, either naïve to treatment or had failed before; or (2) failed in previous amoxicillin‐containing therapies. All enrolled patients accepted 14‐day vonoprazan and tetracycline dual therapy (VT dual therapy) as follows: vonoprazan (20 mg b.i.d.) and tetracycline (500 mg t.i.d. [body weight < 70 kg] or 500 mg q.i.d. [body weight ≥ 70 kg]). H. pylori status was evaluated by 13C‐urease breath test 6 weeks after treatment. All adverse effects were recorded. Some patients underwent bacterial culture and antibiotic susceptibility testing.ResultsA total of 62 patients were enrolled; 18 of them received VT dual therapy as first‐line treatment, 44 patients received VT dual therapy as rescue treatment. Overall, 58 of 62 patients achieved successful eradication (93.5%), while all involved (100%,18/18) succeeded in the first‐line treatment group and 40 cases (90.9%, 40/44) succeeded in the rescue treatment group. Sixty‐one (61/62, 98.4%) patients completed the whole course of treatment. Adverse events occurred in 6 patients (6/62, 9.7%), while one patient quit because of skin rash. All adverse effects were mild and relieved spontaneously after H. pylori treatment. Five patients achieved successful H. pylori culture, and all strains isolated were sensitive to tetracycline.ConclusionsFor the treatment of H. pylori infection in special populations with penicillin allergy or failed in previous amoxicillin‐containing therapies, a 14‐day vonoprazan and tetracycline dual therapy was effective and safe as first‐line and rescue treatment in our study. Further study is warranted to verify its efficacy, especially for those who cannot use amoxicillin.

Publisher

Wiley

Subject

Infectious Diseases,Gastroenterology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3